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The primary focus of research into the pathophysiology of the acute respiratory distress syndrome (ARDS) has been
on the interaction between the lung, underlying causes of ARDS, and the role of white blood cells and platelets in
contributing to lung injury. Given a lack of specific therapies for this common complication of critical illness, further
insight into the pathophysiology of this syndrome is greatly needed to develop targeted interventions. The red
blood cell (RBC) has been reported to undergo deleterious changes in critical illness and be present in the alveoli
of patients with ARDS. Release of RBC contents is known to be injurious in other conditions but has only recently
been studied in critical illness and ARDS. The contribution of the RBC to ARDS represents a new avenue of research
that may produce new, targeted therapies for this deadly syndrome.
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The acute respiratory distress syndrome (ARDS) fre-
quently complicates critical illness from a variety of
underlying causes [1,2]. This syndrome of acute lung in-
flammation and non-cardiogenic pulmonary edema is
associated with significant morbidity and mortality dur-
ing the acute hospitalization along with poor long-term
outcomes including reduced functional status and in-
creased mortality even beyond the initial hospitalization
[3,4]. Although processes of care interventions such as
lung protective ventilation [5], prone positioning [6],
and neuromuscular blockade [7] may be beneficial, there
are no specific pharmacologic interventions to improve
outcomes in this patient population. The lack of targeted
pharmacologic therapies may be a result of an incom-
plete understanding of the underlying pathophysiology
of ARDS.
Since the first description of ARDS in 1967 [8], inves-
tigation into the pathophysiology of ARDS has focused
on the interaction between the underlying cause, the* Correspondence: lorraine.ware@vanderbilt.edu
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unless otherwise stated.lung endothelium, vasculature, and epithelium, and cir-
culating white blood cells and platelets [1]. In the case
of direct injury to the lung epithelium by pneumonia,
for example, there is an increase in epithelial permeabil-
ity, and normal clearance of fluid from the alveolus is
disrupted [9,10]. The pulmonary capillary endothelium
is also disrupted causing an influx of proteinacious fluid
and white blood cells into the alveolus resulting in dif-
fuse pulmonary inflammation and coagulation [11].
Given the known inflammation and coagulation that
occur with ARDS, pharmacologic therapies have focused
on these targets to try to improve clinical outcomes but
with no benefit [12-14]. The red blood cell (RBC) also
crosses the pulmonary capillary endothelium and can be
found in the alveoli of patients with ARDS [1,8,15] but
until recently has primarily been viewed as a bystander
to the alveolar inflammation and coagulation that occurs
in ARDS.
The purpose of this review is to examine the changes
that occur to the RBC in critical illness, the contribution
of the RBC to alveolar injury in ARDS, and potential in-
terventions for future study.Review
The red blood cell in critical illness
It was first reported over 20 years ago that the RBC cell
membrane undergoes changes and is damaged as aal. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hemolytic condition [16]. The RBC membrane becomes
less deformable resulting in damage to the membrane
when the RBC transits capillary beds [16,17]. The de-
creased deformability of the RBC is associated with an
increase in systemic oxidative injury and worse clinical
outcomes in critical illness including an increase in the
number of failing organ systems [16].
Sepsis, the most common cause of indirect ARDS [1],
has received the most attention regarding the contribution
of systemic illness to damage of the RBC. As a result of
the systemic inflammation and coagulation seen in sepsis,
there are significant changes in the microcirculation [18],
vascular reactivity [19], platelet aggregation, and white
blood cell adhesion to the endothelium [18,20]. These
changes in the vascular endothelium and interaction
between white blood cells and the RBC result in lipid
peroxidation of the RBC membrane, alteration of RBC
membrane pumps, an influx of calcium into the RBC,
and changes in 2,3-diphosphoglycerate levels [21]. All
of these contribute to decreased RBC deformability and
an increase in RBC aggregation and occlusion of micro-
vascular beds that contribute to organ dysfunction [21].
In addition to occlusion of capillary beds, decreased
deformability of RBCs in critical illness also leads to
RBC lysis and release of intracellular contents into the
circulation. In an experimental model [22], plasma from
humans with sepsis was incubated with normal RBCs
from healthy volunteers, and changes in the RBC mem-
brane were examined. Exposure of healthy RBCs to
plasma from patients with sepsis resulted in binding of
annexin V indicative of phosphatidylserine exposure on
the outer leaflet, influx of calcium into the RBC leading
to RBC aggregation, and an increase in RBC lysis. None
of these deleterious effects occurred when normal RBCs
were incubated with plasma from non-septic patients.
Lysis of RBCs in the intravascular and alveolar spaces re-
sults in the release of potentially injurious mediators in-
cluding cell-free hemoglobin (CFH) that can contribute
to organ dysfunction and mortality.
Cell-free hemoglobin as a mediator of disease
Hemoglobin exists in the red blood cell as a tetramer of
globin molecules with ferrous (2+) iron bound to each of
the four porphyrin-ring heme groups [23]. During normal
RBC turnover in healthy humans, any hemoglobin re-
leased from the RBC into the circulation is cleared via
binding of hemoglobin to haptoglobin leading to CD163
receptor-mediated uptake into the macrophage where
hemoglobin is converted to bilirubin by heme oxygenase-1
(HO-1) and ultimately excreted by the liver [24]. Free
heme is bound and cleared by binding to hemopexin and
macrophage processing by the same mechanisms [24]. Of
the hemoglobin processing proteins, HO-1 has receivedthe most attention in past research in critical illness and is
known to: (1) Be upregulated in inflammatory and pro-
oxidant disease states such as sepsis and ARDS, (2) Be
expressed by multiple cell types in the lung, and (3) De-
crease pulmonary inflammation and vascular remodeling
in animal models of lung injury [25]. Changes in HO-1
levels have been observed in patients with ARDS, asthma,
COPD, cystic fibrosis, idiopathic pulmonary fibrosis, and
lung cancer, and increased levels of HO-1 are associated
with decreased acute lung injury [25].
These processes of cell-free hemoglobin (CFH) clear-
ance protect against the four main mechanisms of CFH-
mediated organ injury: nitric oxide (NO) consumption,
endothelial damage, inflammation, and oxidative injury
(Figure 1). Nitric oxide consumption by CFH only oc-
curs when hemoglobin is released from the RBC into
the plasma, and hemoglobin has no significant effect on
NO when it is compartmentalized in the red blood cell
[26]. In patients with sickle cell disease, a condition
characterized by intravascular hemolysis and release of
up to 30 grams of CFH from the RBC per day, in-
creases in plasma heme were strongly correlated with
an increase in NO consumption and peripheral vaso-
constriction which could be reversed with inhaled NO
[27]. In a guinea pig model of RBC transfusion, animals
transfused with RBCs with a storage duration of 28
days had significantly increased levels of plasma heme
compared to animals transfused with RBCs stored for 2
days, and transfusion with RBCs stored for 28 days
caused extensive endothelial damage to the vasculature
and kidney [28]. Treatment with the CFH scavenger
haptoglobin prevented transfusion-induced endothelial
damage to both the vasculature and kidney in this
model. When alveolar epithelial cells are exposed to
CFH, release of inflammatory cytokines occurs via the
NF-κB pathway, and this inflammatory response is in-
dependent of iron oxidation [29]. Finally, when
hemoglobin is released from the RBC into an oxidative
environment, the ferrous (Fe 2+) iron moiety becomes
oxidized to the ferryl (Fe 4+) state, and this ferryl radical is
capable of inducing oxidative injury [23]. In an animal
model of rhabdomyolysis, characterized by the release of
the hemoprotein myoglobin and acute kidney injury,
animals with induced rhabdomyolysis had significantly
elevated levels of ferryl myoglobin, an increase in oxidative
injury as measured by F2-Isoprostanes, and an increase in
plasma creatinine [30]. Supplementation with acetamino-
phen, a potent ferryl hemoglobin reductant, prevented the
increase in ferryl myoglobin, F2-Isoprostanes, and plasma
creatinine.
A number of disease states are characterized by the re-
lease of CFH from the RBC and include sickle cell anemia
[27], hemodialysis [31], cardiac bypass [32], red blood cell
transfusion [33], pulmonary arterial hypertension [34], and
Figure 1 Pathologic mechanisms of the action of plasma cell-free hemoglobin. The pathologic mechanisms by which plasma or air-space
cell-free hemoglobin can contribute to organ dysfunction and death in ARDS include nitric oxide consumption, oxidative injury, inflammation,
and endothelial injury.
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consumption, endothelial damage, and oxidative injury by
CFH have been associated with poor clinical outcomes in-
cluding acute kidney injury [32,38,39], myocardial infarc-
tion [40], and death [35,40,41]. There has been recent
interest in the role of CFH in the pathophysiology of sepsis,
the most common cause of ARDS, where CFH can be
detected in the plasma of 80% of patients [35,37] and
increased levels are associated with an increased risk of
in-hospital mortality [35]. Additionally, in experimental
animal models of sepsis, blocking the deleterious effects
of CFH with the heme-binding protein hemopexin resulted
in reduced organ injury and mortality [42].
Compared to other disease states associated with CFH
release from RBCs, critically ill patients with sepsis have
a unique physiologic state that creates an environment
where CFH can induce organ injury due to a “two-hit”
set of conditions. First, critically ill patients, including
those with sepsis, are known to have a reduced capacity
to detoxify CFH. Decreased levels of haptoglobin, hemo-
pexin, and heme oxygenase-1 occur in critical illness, in-
cluding patients with sepsis and ARDS, and decreased
levels have been associated with poor clinical outcomes
[25,43]. Second, this reduced capacity to detoxify CFH is
combined with the oxidative environment that occurs in
critical illness [44] that can cause oxidation of the iron
moiety of CFH from the ferrous (2+) to the ferric (3+)
and the ferryl (4+) state [23]. Both ferric hemoglobin
(methemoglobin) and the ferryl hemoglobin radical can
be injurious [29]. The ferryl radical is capable of causing
organ injury via peroxidation of lipid membranes. Prod-
ucts of lipid peroxidation, including F2-Isoprostanes andIsofurans, can be detected in critically ill patients and
are associated with organ dysfunction [35,44].
Cell-free hemoglobin and ARDS
Alveolar hemorrhage was noted in the first description of
ARDS [8]; however, until recently, the presence of RBCs
in the alveoli has been viewed primarily as a marker of al-
veolar capillary barrier permeability and disease severity
rather than a pathologic mediator of injury. The oxidative
environment and lack of hemoglobin processing proteins
in the alveoli during ARDS [1,15,25] create an ideal envir-
onment for RBCs that have traversed the pulmonary
endothelium and epithelium to cause injury. In animal
studies of ARDS, RBCs are known to break down and
release CFH into the alveoli; air-space levels of CFH are
associated with the severity of acute lung injury and
increased markers of lipid peroxidation [15]. Additionally,
instillation of RBCs or CFH into the airways of rats induces
acute lung injury [45]. Pulmonary inflammation from in-
stillation of whole blood into the trachea can be attenuated
by upregulating the production of haptoglobin, resulting in
a decrease in inflammatory cells, alveolar LDH, protein,
and macrophage inflammatory protein-2 [46]. Finally, the
provision or upregulation of heme oxygenase-1, a protein
that is important in the processing of CFH, in animal
models of lung injury resulted in reduced lung injury from
a variety of injury mechanisms [25,47-50].
An additional mechanism of injury by CFH in ARDS
may be mediated specifically by targeted cell surface re-
ceptor binding on the alveolar epithelium rather than
oxidative injury by the ferryl hemoglobin radical. In an
in vitro study of human alveolar epithelial cells [29],
Figure 2 The percentage of patients with sepsis that developed
ARDS after transfusion with red blood cells of varying storage
duration. A total of 96 critically ill patients with sepsis were analyzed
in a retrospective cohort study, all of whom received at least one
transfusion of red blood cells. Patients who received red blood cells
of a longer storage duration had an associated increased risk of
subsequently developing ARDS. Gray bars represent the percentage
of transfused patients with sepsis who developed ARDS after
transfusion. Circles at the top and bottom represent individual
patients with (top) and without (bottom) ARDS and the median age
of transfused red blood cells received. The red line and 95% confidence
band represent the probability of developing ARDS derived from a
multivariable logistic regression model. The patients included in this
study did not carry the diagnosis of transfusion-related acute lung
injury (TRALI) as they already had a risk factor for ARDS (sepsis),
and ARDS that occurred in this study was beyond the 6-hour window
for the diagnosis of TRALI. Figure reproduced with permission from
SpringerOpen, copyright 2013 [55].
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stimulated the release of IL-8 and monocyte chemo-
attractant protein-1 via activation of the NF-κB pathway.
The supplementation of antioxidants or iron chelators
did not alter the effects of methemoglobin, suggesting
that CFH can mediate alveolar epithelial injury inde-
pendent of iron and oxidative pathways.
Several lines of evidence suggest that CFH also plays a
role in human ARDS. In an observational study of 41 pa-
tients with ARDS or hydrostatic pulmonary edema [15],
undiluted pulmonary edema samples were obtained via
endotracheal tube suctioning. Patients with ARDS had sig-
nificantly higher levels of CFH compared with control pa-
tients with hydrostatic pulmonary edema. Also, in patients
with diffuse alveolar hemorrhage, alveolar fluid obtained
via bronchoalveolar lavage showed increasing levels of
biomarkers of oxidative injury as the lavage became pro-
gressively bloodier. Pulmonary arterial hypertension
(PAH) is known to occur during ARDS and is associated
with poor outcomes [51,52]. In humans with chronic
PAH, plasma CFH is detectable, and increased levels of
CFH are associated with increased pulmonary artery pres-
sures, pulmonary vascular resistance, and decreased car-
diac index. Additionally, patients with increased plasma
CFH had an associated increased risk of PAH-related
hospitalization [34]. Whether these findings are relevant
to the acute PAH that develops in patients with ARDS is
an important topic for future study. Finally, as previously
mentioned, transfusion of RBCs, including RBCs of a lon-
ger storage duration, results in an increase in plasma CFH
and vascular permeability [33,53,54] and is associated with
an increased risk of developing ARDS in critically ill pa-
tients with sepsis (Figure 2) [55].
Potential therapeutic interventions
Although we still have a limited understanding of the role
of RBCs and CFH in the pathogenesis of ARDS, in other
disease states associated with release of CFH, there are
therapeutic interventions being developed to improve clin-
ical outcomes. Preliminary studies support a potential
benefit of targeting CFH in sickle cell anemia, malaria,
sepsis, and other conditions associated with release of
CFH. These conditions are more common than ARDS
and have some preliminary data regarding the benefit of
CFH-inhibition and outcomes. As previously discussed,
there are a number of processing proteins required to de-
toxify CFH to bilirubin including haptoglobin, hemopexin,
and heme oxygenase-1 [24]. Animal models of diseases as-
sociated with CFH release have focused on supplementa-
tion with these proteins to prevent organ dysfunction. In
an animal model of RBC transfusion, an intervention
known to increase plasma levels of CFH in the recipient,
transfusion of RBCs with a long storage duration in-
creased plasma levels of CFH and caused injury to thevascular endothelium and renal injury [28]. Supplementa-
tion with haptoglobin completely attenuated the effects of
transfusion-induced CFH on the endothelium and kidney.
In a separate animal model of sepsis, CFH was found to
be elevated and associated with hepatic and renal injury;
supplementation with hemopexin to target free heme re-
versed the effects of CFH in these animals [42]. Finally,
supplementation of heme oxygenase-1 to animals with
lung injury results in decreased inflammation and alveolar
fluid accumulation [25,47,48,50].
Small studies of haptoglobin as a therapeutic CFH
scavenger have been conducted in humans with a variety
of conditions [56]. In patients undergoing extracorporeal
circulation, transfusion with RBCs, or who have acute
hemolytic conditions, supplementation with between 3–
45 grams of haptoglobin were associated with improved
renal function [57-64]; however none of these studies
were randomized controlled trials, and some reports in-
cluded only a single patient receiving haptoglobin as a
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ical use in Japan and is not available in the USA.
Acetaminophen has a number of pharmacologic mecha-
nisms, including prostaglandin H2 synthase and cyclooxy-
genase inhibition, that are used to treat pain and fever
[65,66]. In addition to these mechanism of action, acet-
aminophen is a specific ferryl hemoglobin reductant that
can inhibit the peroxidase activity of oxidized hemoglobin
by reducing the ferryl (4+) hemoglobin radical to the ferric
(3+) state [23,66]. In an animal study of rhabdomyolysis
where the hemoprotein myoglobin is released into the
plasma, animals supplemented with acetaminophen before
and after the induction of rhabdomyolysis had reduced
oxidative injury as measured by plasma F2-Isoprostanes
and improved renal function compared with placebo [30].
As previously discussed, extracorporeal circulation of the
blood is associated with release of CFH into the plasma,
and increased plasma CFH levels are associated with an
increased risk of kidney injury [32,67]. In a randomized,
placebo-controlled trial of intravenous acetaminophen in
pediatric patients undergoing cardiopulmonary bypass,
bypass significantly increased CFH, and treatment with
intravenous acetaminophen resulted in attenuated oxida-
tive injury compared to placebo [67]. Observational studies
of CFH and acetaminophen in critically ill adults with
sepsis have shown an association of increased CFH
with increased mortality and attenuation of this effect
and reduced oxidative injury when patients received
acetaminophen as part of their usual care [35]. In a
randomized trial of critically ill adults with severe sepsis
and detectable plasma CFH, treatment with enteral acet-
aminophen resulted in a reduction of oxidative injury and
improved renal function compared to placebo [36]. As
sepsis is the most common underlying cause of ARDS,
these findings provide proof of principle that a therapy
that targets CFH may be beneficial in ARDS.
No studies to date have examined the efficacy and safety
of CFH-targeted therapies such as haptoglobin, hemo-
pexin, heme oxygenase-1, or acetaminophen in humans
with ARDS. As we continue to make further insights into
the role of the RBC and CFH in the pathogenesis of
ARDS, we are likely to see these and other therapies tested
in patients with ARDS.
Conclusions
ARDS is a common and incompletely understood syn-
drome without targeted therapies. Until recently, investi-
gation into the pathophysiology of ARDS focused on the
interaction between white blood cells, platelets, and the
pulmonary endothelium and epithelium. The red blood
cell, known to be present in the alveoli of patients with
ARDS, has previously been viewed as an innocent by-
stander rather than a major driver of the pathogenesis of
ARDS. New insights into the changes that occur in theRBC membrane during critical illness and the role of cell-
free hemoglobin in oxidative and endothelial injury have
renewed interest in the RBC as a pathologic mediator in
ARDS. Further study is needed to better characterize the
red blood cell’s role in the pathogenesis of ARDS; however,
this line of research is already producing investigation into
new therapeutic approaches in ARDS.
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